*Storage:
*Shipping:
CAS No. : | 157716-52-4 |
Formula : | C25H52NO4P |
M.W : | 461.66 |
SMILES Code : | O=P(OC1CC[N+](C)(C)CC1)([O-])OCCCCCCCCCCCCCCCCCC |
Synonyms : |
KRX-0401; NSC 639966; NKA17
|
InChI Key : | SZFPYBIJACMNJV-UHFFFAOYSA-N |
Pubchem ID : | 148177 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
| Concentration | Treated Time | Description | Reference |
TB3 cells | 2.5 μM, 5 μM | 6 h or 24 h | Pretreatment with perifosine blocked BDNF/TrkB-induced Akt phosphorylation and inhibited BDNF's protection of TB3 cells from etoposide treatment. | PMC3158972 |
TB3 cells | 5 μM | 6 h | Pretreatment with perifosine blocked BDNF/TrkB-mediated rescue of TB3 cells from etoposide-induced cell death. | PMC3158972 |
TB3 cells | 2.5 μM, 5 μM | 6 h, 24 h | Perifosine inhibited BDNF/TrkB-induced Akt phosphorylation and blocked BDNF's protection of TB3 cells | PMC3158972 |
PANC-1 | 1–500μM | 72 h | Perifosine significantly inhibited the growth of PANC-1 cells with an IC50 value of 5.1μM. | PMC5219723 |
LPC028 | 1–500μM | 72 h | Perifosine significantly inhibited the growth of LPC028 cells and synergistically enhanced the antiproliferative activity of gemcitabine with a CI value of 0.2. | PMC5219723 |
LPC006 | 1–500μM | 72 h | Perifosine showed weaker growth inhibition in LPC006 cells with an IC50 value of 22.5μM, and the combination with gemcitabine was antagonistic. | PMC5219723 |
U251 cells | 10 μM | 30 min | Inhibit AKT protein, reduce TNTs formation and mitochondrial transfer induced by nanomaterials | PMC10789074 |
H460 | 1 µM to 20 µM | 24 h | To evaluate the effect of Perifosine on cell survival, the results showed that Perifosine inhibited the survival of H460 cells. | PMC2789206 |
H157 | 1 µM to 20 µM | 24 h | To evaluate the effect of Perifosine on cell survival, the results showed that Perifosine inhibited the survival of H157 cells. | PMC2789206 |
H358 | 1 µM to 20 µM | 24 h | To evaluate the effect of Perifosine on cell survival, the results showed that Perifosine inhibited the survival of H358 cells. | PMC2789206 |
H226 | 1 µM to 20 µM | 24 h | To evaluate the effect of Perifosine on cell survival, the results showed that Perifosine inhibited the survival of H226 cells. | PMC2789206 |
MM.1S cells | 5 µM | 2 h | Perifosine inhibited Akt phosphorylation, enhancing rapamycin-induced cytotoxicity. | PMC3096071 |
MM.1S cells | 5 µM | 3 h | Perifosine augmented rapamycin-induced autophagy. | PMC3096071 |
In Vivo:
Species
| Animal Model
| Administration | Dosage | Frequency | Description | Reference |
Mice | Radiation-induced lung injury model | Not specified | 250 mg/kg | Once per week for 3, 7, and 14 days | Suppressed the regenerative effects of Sox9-expressing cells, leading to thickened alveolar septa and aggravated pulmonary fibrosis | PMC8254240 |
BALB/c nude mice | osteosarcoma xenograft model | oral | 36 mg/kg | once daily for 2 weeks | Perifosine inhibits tumor proliferation and promotes apoptosis of osteosarcoma cells | PMC8214859 |
nude mice | TB3 tumor model | oral gavage | 15 mg/kg | once daily for 30 days | Perifosine treatment inhibited Akt phosphorylation in tumor tissues and increased the sensitivity of TB3 neuroblastoma tumors to etoposide treatment. | PMC3158972 |
Nude mice | TB3 tumor model | Oral | 15 mg/kg | Once daily for 30 days | Perifosine inhibited Akt phosphorylation and increased the sensitivity of TB3 tumors to etoposide | PMC3158972 |
nude mice | H460 xenograft model | oral | 15–10 mg/kg | once daily for 14 days | To evaluate the inhibitory effect of Perifosine alone or in combination with chloroquine on H460 xenografts, the results showed that Perifosine combined with chloroquine significantly inhibited tumor growth. | PMC2789206 |
CB-17 SCID mice | Multiple myeloma mouse xenograft model | Oral gavage | 125 mg/kg | Once weekly for 4 weeks | Perifosine combined with nab-rapamycin significantly inhibited tumor growth and prolonged survival. | PMC3096071 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01555281 | Multiple Myeloma | Phase 1 Phase 2 | Active, not recruiting | December 2019 | Italy ... More >> Istituto Europeo di Oncologia IEO Milano, Italy, 20141 University of Torino Torino, Italy, 10127 Switzerland Kantonsspital Aarau Aarau, Switzerland, 5001 Kantonsspital Baden Baden, Switzerland, 5404 Istituto Oncologico Svizzera Italiana IOSI Bellinzona, Switzerland, 6500 Inselspital Bern Bern, Switzerland, 3010 Kantonsspital Graubünden Chur, Switzerland, 7000 Kantonsspital Olten Olten, Switzerland, 4600 Kantonsspital St. Gallen St. Gallen, Switzerland, 9007 Regionalspital Thun, Switzerland, 3600 UniversitätsSpital Zürich Zürich, Switzerland, 8091 Less << |
NCT00055380 | Cancer | Phase 1 | Completed | - | United States, Maryland ... More >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Less << |
NCT00053794 | Endometrial Cancer ... More >> Sarcoma Less << | Phase 2 | Completed | - | Canada, Alberta ... More >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Island Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Canada, Quebec Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada, H1T 2M4 Less << |
NCT00053781 | Melanoma (Skin) | Phase 2 | Completed | - | Canada, Alberta ... More >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, Nova Scotia Nova Scotia Cancer Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital at University Health Network Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Centre Hospitalier de l'Universite de Montreal Montreal, Quebec, Canada, H2L-4M1 McGill University Montreal, Quebec, Canada, H2W 1S6 Less << |
NCT00019656 | Leukemia Lymp... More >>homa Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Completed | - | United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Less << |
NCT00054145 | Breast Cancer | Phase 2 | Completed | - | Canada, Ontario ... More >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 1C4 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00060437 | Prostate Cancer | Phase 2 | Completed | - | United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Less << |
NCT00005794 | Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << | Phase 1 | Completed | - | United States, Wisconsin ... More >> University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 Less << |
NCT00053924 | Pancreatic Cancer | Phase 2 | Completed | - | Canada, Ontario ... More >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00064324 | Recurrent Adult Soft Tissue Sa... More >>rcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Less << | Phase 2 | Completed | - | United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT00431054 | Ovarian Cancer | Phase 1 | Completed | - | United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01097018 | Colorectal Cancer | Phase 3 | Completed | - | - |
NCT00399126 | Neoplasms | Phase 1 | Completed | - | United States, Tennessee ... More >> AOI Pharmaceuticals Investigative Site Johnson City, Tennessee, United States, 37604 Less << |
NCT00399087 | Neoplasms | Phase 1 | Completed | - | United States, Tennessee ... More >> Investigative Site Johnson City, Tennessee, United States, 37604 Less << |
NCT00062387 | Head and Neck Cancer | Phase 2 | Terminated(Administratively co... More >>mplete.) Less << | - | United States, Illinois ... More >> University of Chicago Cancer Research Center Chicago, Illinois, United States, 60637-1470 Decatur Memorial Hospital Cancer Care Institute Decatur, Illinois, United States, 62526 Evanston Northwestern Health Care - Evanston Hospital Evanston, Illinois, United States, 60201-1781 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 LaGrange Memorial Hospital LaGrange, Illinois, United States, 60525 Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood, Illinois, United States, 60153 Oncology/Hematology Associates of Central Illinois, P.C. Peoria, Illinois, United States, 61602 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62701 United States, Indiana Fort Wayne Medical Oncology and Hematology, Incorporated Fort Wayne, Indiana, United States, 46885-5099 CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Michigan Oncology Care Associates, P.L.L.C. Saint Joseph, Michigan, United States, 49085 United States, Wisconsin Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States, 53226 Less << |
NCT00301938 | Accelerated Phase Chronic Myel... More >>ogenous Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Neoplasms Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia T-cell Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia Less << | Phase 1 | Completed | - | United States, Maryland ... More >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Less << |
NCT00415064 | Multiple Myeloma | Phase 1 | Completed | - | United States, Michigan ... More >> Ann Arbor, Michigan, United States, 48109 Less << |
NCT00398697 | Neoplasms | Phase 1 | Completed | - | United States, Tennessee ... More >> Johnson City, Tennessee, United States, 37604 Less << |
NCT02238496 | Brain Tumor, Recurrent ... More >> Glioblastoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Mixed Glioma Less << | Phase 2 | Unknown | December 2016 | United States, New York ... More >> Columbia University Medical Center New York City, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York City, New York, United States, 10065 Less << |
NCT00059982 | Pancreatic Cancer | Phase 2 | Completed | - | United States, Illinois ... More >> CCOP - Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Indiana CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Iowa CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States, 50309-1016 United States, Massachusetts Tufts - New England Medical Center Boston, Massachusetts, United States, 02111 United States, Minnesota CCOP - Duluth Duluth, Minnesota, United States, 55805 Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 CCOP - Metro-Minnesota Saint Louis Park, Minnesota, United States, 55416 United States, New York MBCCOP-Our Lady of Mercy Cancer Center Bronx, New York, United States, 10466 United States, North Dakota CCOP - Merit Care Hospital Fargo, North Dakota, United States, 58122 United States, Texas CCOP - Scott and White Hospital Temple, Texas, United States, 76508 Less << |
NCT00399152 | Renal Cancer ... More >>GIST Less << | Phase 1 | Completed | - | - |
NCT00398814 | Renal Cancer ... More >>Tumors Less << | Phase 1 | Completed | - | - |
NCT00058214 | Adenocarcinoma of the Prostate... More >> Recurrent Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer Stage IV Prostate Cancer Less << | Phase 2 | Terminated(Did not meet interi... More >>m stopping criteria for continuation to the second stage.) Less << | - | United States, California ... More >> UC Davis Cancer Center Sacramento, California, United States, 95817 Less << |
NCT00401388 | Chondrosarcomas ... More >> Alveolar Soft Part Sarcomas Extra Skeletal Myxoid Chondrosarcomas Less << | Phase 2 | Completed | - | - |
NCT00422656 | Waldenstrom's Macroglobulinemi... More >>a Less << | PHASE2 | COMPLETED | 2025-11-12 | Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less << |
NCT00422656 | Waldenstrom's Macroglobulinemi... More >>a Less << | PHASE2 | COMPLETED | 2025-11-12 | Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less << |
NCT01051557 | - | Terminated | - | - | |
NCT00399789 | Non Small Cell Lung Cancer | PHASE1|PHASE2 | COMPLETED | 2025-12-11 | AOI Pharmaceuticals Investigat... More >>ive Site, Tucson, Arizona, 85704, United States|AOI Pharmaceuticals Investigative Site, Pomona, California, 91767, United States|AOI Pharmaceuticals Investigative Site, Aventura, Florida, 33180, United States|AOI Pharmaceuticals Investigative Site, Hollywood, Florida, 33021, United States|AOI Pharmaceuticals Investigative Site, Lakeland, Florida, 33805, United States|AOI Pharmaceuticals Investigative Site, Ormond Beach, Florida, 32174, United States|AOI Pharmaceuticals Investigative Site, Lawrenceville, Georgia, 30045, United States|AOI Pharmaceuticals Investigative Site, Galesburg, Illinois, 61401, United States|AOI Pharmaceuticals Investigative Site, New Albany, Indiana, 47150, United States|AOI Pharmaceuticals Investigative Site, Grand Rapids, Michigan, 49546, United States|AOI Pharmaceuticals Investigative Site, Kalamazoo, Michigan, 49048, United States|AOI Pharmaceuticals Investigative Site, Billings, Montana, 59101, United States|AOI Pharmaceuticals Investigative Site, Albuquerque, New Mexico, 87109, United States|AOI Pharmaceuticals Investigative Site, Albany, New York, 12208, United States|AOI Pharmaceuticals Investigative Site, Armonk, New York, 10504, United States|AOI Pharmaceuticals Investigative Site, Greenville, South Carolina, 29605, United States|AOI Pharmaceuticals Investigative Site, Chattanooga, Tennessee, 37404, United States|AOI Pharmaceuticals Investigative Site, Nashville, Tennessee, 37203, United States|AOI Pharmaceuticals Investigative Site, Dallas, Texas, 75237, United States|AOI Pharmaceuticals Investigative Site, Dallas, Texas, 75246, United States|AOI Pharmaceuticals Investigative Site, Tyler, Texas, 75702, United States Less << |
NCT01051557 | Adult Anaplastic Astrocytoma ... More >> Adult Anaplastic Oligodendroglioma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Oligodendroglioma Recurrent Adult Brain Neoplasm Less << | Phase 1 Phase 2 | Terminated | - | United States, New Jersey ... More >> Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT00058214 | - | Terminated(Did not meet interi... More >>m stopping criteria for continuation to the second stage.) Less << | - | - | |
NCT00401011 | Multiple Myeloma ... More >> Multiple Myeloma in Relapse Less << | Phase 1 Phase 2 | Completed | - | - |
NCT00391560 | Leukemia | Phase 2 | Completed | - | - |
NCT00398879 | Colon Cancer | Phase 2 | Completed | - | - |
NCT00398710 | Waldenstr?m's Macroglobulinemi... More >>a Less << | PHASE2 | COMPLETED | 2025-10-11 | Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less << |
NCT00776867 | Solid Tumors | Phase 1 | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT00498966 | Kidney Cancer | PHASE2 | COMPLETED | 2025-10-11 | Investigative Site, Louisville... More >>, Kentucky, 40202, United States|Investigative Site, Morristown, New Jersey, 07962, United States|Investigative Site, Armonk, New York, 10504, United States Less << |
NCT00847366 | Non Small Cell Lung Cancer ... More >> Solid Tumors Metastatic Breast Cancer Sarcomas Less << | Not Applicable | Completed | - | - |
NCT01002248 | Multiple Myeloma | Phase 3 | Terminated | - | - |
NCT00455559 | Gastrointestinal Stromal Tumor... More >>s Less << | Phase 2 | Completed | - | - |
NCT00448721 | Renal Cell Carcinoma | PHASE2 | COMPLETED | 2025-10-11 | Investigative Site, Duarte, Ca... More >>lifornia, 91010, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Investigative Site, Philadelphia, Pennsylvania, 19104, United States|Investigative Site, Nashville, Tennessee, 37232, United States Less << |
NCT00375791 | Multiple Myeloma | Phase 2 | Completed | - | United States, California ... More >> Investigative Site Berkeley, California, United States, 94704 Investigative Site Duarte, California, United States, 91010 United States, Georgia Investigative Site Atlanta, Georgia, United States, 30322 United States, Illinois Investigative Site Chicago, Illinois, United States, 60611 United States, Massachusetts Investigative Site Boston, Massachusetts, United States, 02115 United States, Michigan Investigative Site Ann Arbor, Michigan, United States, 48103 United States, Virginia Investigative Site Charlottesville, Virginia, United States, 22908 Less << |
NCT00873457 | Chronic Lymphocytic Leukemia ... More >> Small Lymphocytic Lymphoma Less << | Phase 2 | Completed | - | United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less << |
NCT00389077 | Tumors|Lymphomas | PHASE2 | COMPLETED | 2025-09-11 | - |
NCT00873457 | - | Completed | - | - | |
NCT01224730 | Cancer | Phase 1 | Completed | - | United States, Texas ... More >> Dallas, Texas, United States, 75230 Houston, Texas, United States, 77030 Less << |
NCT01048580 | Colon Cancer | Phase 1 | Completed | - | - |
NCT00590954 | Malignant Gliomas|CNS|Brain Ca... More >>ncer|Cancer Less << | PHASE2 | COMPLETED | 2019-11-11 | Memorial Sloan-Kettering Cance... More >>r Center, New York, New York, 10065, United States Less << |
NCT01049841 | Pediatric Solid Tumors | Phase 1 | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 2.17mL 0.43mL 0.22mL | 10.83mL 2.17mL 1.08mL | 21.66mL 4.33mL 2.17mL |
Tags: 157716-52-4 synthesis path| 157716-52-4 SDS| 157716-52-4 COA| 157716-52-4 purity| 157716-52-4 application| 157716-52-4 NMR| 157716-52-4 COA| 157716-52-4 structure
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL